1now Citations

Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

J Mol Biol 327 1093-109 (2003)
Related entries: 1nou, 1np0

Cited: 127 times
EuropePMC logo PMID: 12662933

Abstract

In humans, two major beta-hexosaminidase isoenzymes exist: Hex A and Hex B. Hex A is a heterodimer of subunits alpha and beta (60% identity), whereas Hex B is a homodimer of beta-subunits. Interest in human beta-hexosaminidase stems from its association with Tay-Sachs and Sandhoff disease; these are prototypical lysosomal storage disorders resulting from the abnormal accumulation of G(M2)-ganglioside (G(M2)). Hex A degrades G(M2) by removing a terminal N-acetyl-D-galactosamine (beta-GalNAc) residue, and this activity requires the G(M2)-activator, a protein which solubilizes the ganglioside for presentation to Hex A. We present here the crystal structure of human Hex B, alone (2.4A) and in complex with the mechanistic inhibitors GalNAc-isofagomine (2.2A) or NAG-thiazoline (2.5A). From these, and the known X-ray structure of the G(M2)-activator, we have modeled Hex A in complex with the activator and ganglioside. Together, our crystallographic and modeling data demonstrate how alpha and beta-subunits dimerize to form either Hex A or Hex B, how these isoenzymes hydrolyze diverse substrates, and how many documented point mutations cause Sandhoff disease (beta-subunit mutations) and Tay-Sachs disease (alpha-subunit mutations).

Articles - 1now mentioned but not cited (16)

  1. Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, James MN. J. Mol. Biol. 327 1093-1109 (2003)
  2. Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis. Matsuoka K, Tamura T, Tsuji D, Dohzono Y, Kitakaze K, Ohno K, Saito S, Sakuraba H, Itoh K. Mol. Ther. 19 1017-1024 (2011)
  3. Structure of human Rad51 protein filament from molecular modeling and site-specific linear dichroism spectroscopy. Reymer A, Frykholm K, Morimatsu K, Takahashi M, Nordén B. Proc. Natl. Acad. Sci. U.S.A. 106 13248-13253 (2009)
  4. Structure of the dimeric N-glycosylated form of fungal beta-N-acetylhexosaminidase revealed by computer modeling, vibrational spectroscopy, and biochemical studies. Ettrich R, Kopecký V, Hofbauerová K, Baumruk V, Novák P, Pompach P, Man P, Plíhal O, Kutý M, Kulik N, Sklenár J, Ryslavá H, Kren V, Bezouska K. BMC Struct. Biol. 7 32 (2007)
  5. Sequence and copy number analyses of HEXB gene in patients affected by Sandhoff disease: functional characterization of 9 novel sequence variants. Zampieri S, Cattarossi S, Oller Ramirez AM, Rosano C, Lourenco CM, Passon N, Moroni I, Uziel G, Pettinari A, Stanzial F, de Kremer RD, Azar NB, Hazan F, Filocamo M, Bembi B, Dardis A. PLoS ONE 7 e41516 (2012)
  6. Computational study of β-N-acetylhexosaminidase from Talaromyces flavus, a glycosidase with high substrate flexibility. Kulik N, Slámová K, Ettrich R, Křen V. BMC Bioinformatics 16 28 (2015)
  7. Crystallization and diffraction analysis of β-N-acetylhexosaminidase from Aspergillus oryzae. Vaněk O, Brynda J, Hofbauerová K, Kukačka Z, Pachl P, Bezouška K, Rezáčová P. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67 498-503 (2011)
  8. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  9. Molecular phylogeny and predicted 3D structure of plant beta-D-N-acetylhexosaminidase. Hossain MA, Roslan HA. ScientificWorldJournal 2014 186029 (2014)
  10. BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair. Jimenez-Sainz J, Mathew J, Moore G, Lahiri S, Garbarino J, Eder JP, Rothenberg E, Jensen RB. Elife 11 e79183 (2022)
  11. Bioinformatics and Network Pharmacology of the First Crystal Structured Clerodin: Anticancer and Antioxidant Potential against Human Breast Carcinoma Cell. Pakrashy S, Mandal PK, Nanda Goswami J, Dey SK, Maiti Choudhury S, Bhattacharya B, Emmerling F, Alasmary FA, Dolai M. ACS Omega 7 48572-48582 (2022)
  12. Molecular docking and GC-MS data for the inhibition of RAD51 expression by a compound from Clerodendrum inerme L. Marikkannu KKA, Ganesan S. Bioinformation 17 767-771 (2021)
  13. One-Pot Surface Modification of β-Cu2O NPs for Biocatalytic Performance against A-549 Lung Carcinoma Cell Lines through Docking Analysis. Abbas G, Pandey G, Singh KB, Gautam N. ACS Omega 6 29380-29393 (2021)
  14. Structural insights of the enzymes from the chitin utilization locus of Flavobacterium johnsoniae. Mazurkewich S, Helland R, Mackenzie A, Eijsink VGH, Pope PB, Brändén G, Larsbrink J. Sci Rep 10 13775 (2020)
  15. The Combined Use of in Silico, in Vitro, and in Vivo Analyses to Assess Anti-cancerous Potential of a Bioactive Compound from Cyanobacterium Nostoc sp. MGL001. Niveshika, Verma E, Maurya SK, Mishra R, Mishra AK. Front Pharmacol 8 873 (2017)
  16. The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination. Schipani F, Manerba M, Marotta R, Poppi L, Gennari A, Rinaldi F, Armirotti A, Farabegoli F, Roberti M, Di Stefano G, Rocchia W, Girotto S, Tirelli N, Cavalli A. Int J Mol Sci 23 8338 (2022)


Reviews citing this publication (11)

  1. The cell biology of lysosomal storage disorders. Futerman AH, van Meer G. Nat. Rev. Mol. Cell Biol. 5 554-565 (2004)
  2. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Kolter T, Sandhoff K. Annu. Rev. Cell Dev. Biol. 21 81-103 (2005)
  3. Covalent inhibitors of glycosidases and their applications in biochemistry and biology. Rempel BP, Withers SG. Glycobiology 18 570-586 (2008)
  4. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, Giugliani R, Mahuran D, Clarke JT. Pediatrics 118 e1550-62 (2006)
  5. Lipid-binding proteins in membrane digestion, antigen presentation, and antimicrobial defense. Kolter T, Winau F, Schaible UE, Leippe M, Sandhoff K. J Biol Chem 280 41125-41128 (2005)
  6. Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells. Tropak MB, Mahuran D. FEBS J. 274 4951-4961 (2007)
  7. Ganglioside biochemistry. Kolter T. ISRN Biochem 2012 506160 (2012)
  8. Host-derived glycans serve as selected nutrients for the gut microbe: human milk oligosaccharides and bifidobacteria. Katayama T. Biosci. Biotechnol. Biochem. 80 621-632 (2016)
  9. Turning down tau phosphorylation. Fischer PM. Nat. Chem. Biol. 4 448-449 (2008)
  10. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders. Ryckman AE, Brockhausen I, Walia JS. Int J Mol Sci 21 E6881 (2020)
  11. New Approaches to Tay-Sachs Disease Therapy. Solovyeva VV, Shaimardanova AA, Chulpanova DS, Kitaeva KV, Chakrabarti L, Rizvanov AA. Front Physiol 9 1663 (2018)

Articles citing this publication (100)

  1. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. J. Biol. Chem. 279 13478-13487 (2004)
  2. Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity. Dennis RJ, Taylor EJ, Macauley MS, Stubbs KA, Turkenburg JP, Hart SJ, Black GN, Vocadlo DJ, Davies GJ. Nat. Struct. Mol. Biol. 13 365-371 (2006)
  3. Bifidobacterium bifidum lacto-N-biosidase, a critical enzyme for the degradation of human milk oligosaccharides with a type 1 structure. Wada J, Ando T, Kiyohara M, Ashida H, Kitaoka M, Yamaguchi M, Kumagai H, Katayama T, Yamamoto K. Appl. Environ. Microbiol. 74 3996-4004 (2008)
  4. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MN. J. Mol. Biol. 359 913-929 (2006)
  5. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT, Mahuran DJ. J. Biol. Chem. 282 9150-9161 (2007)
  6. Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans. Ramasubbu N, Thomas LM, Ragunath C, Kaplan JB. J. Mol. Biol. 349 475-486 (2005)
  7. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, Tropak MB. Mol. Genet. Metab. 102 6-12 (2011)
  8. High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Tropak MB, Blanchard JE, Withers SG, Brown ED, Mahuran D. Chem. Biol. 14 153-164 (2007)
  9. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Dorfmueller HC, Borodkin VS, Schimpl M, van Aalten DM. Biochem. J. 420 221-227 (2009)
  10. An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. Martin DR, Krum BK, Varadarajan GS, Hathcock TL, Smith BF, Baker HJ. Exp. Neurol. 187 30-37 (2004)
  11. A compendium of inborn errors of metabolism mapped onto the human metabolic network. Sahoo S, Franzson L, Jonsson JJ, Thiele I. Mol Biosyst 8 2545-2558 (2012)
  12. Structural determinants of an insect beta-N-Acetyl-D-hexosaminidase specialized as a chitinolytic enzyme. Liu T, Zhang H, Liu F, Wu Q, Shen X, Yang Q. J. Biol. Chem. 286 4049-4058 (2011)
  13. Characterization and expression of the beta-N-acetylhexosaminidase gene family of Tribolium castaneum. Hogenkamp DG, Arakane Y, Kramer KJ, Muthukrishnan S, Beeman RW. Insect Biochem. Mol. Biol. 38 478-489 (2008)
  14. Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases. Dorfmueller HC, Borodkin VS, Schimpl M, Zheng X, Kime R, Read KD, van Aalten DM. Chem. Biol. 17 1250-1255 (2010)
  15. Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation. Wendeler M, Hoernschemeyer J, Hoffmann D, Kolter T, Schwarzmann G, Sandhoff K. Eur. J. Biochem. 271 614-627 (2004)
  16. Hexosaminidase assays. Wendeler M, Sandhoff K. Glycoconj. J. 26 945-952 (2009)
  17. Identification and expression analysis of Drosophila melanogaster genes encoding beta-hexosaminidases of the sperm plasma membrane. Cattaneo F, Pasini ME, Intra J, Matsumoto M, Briani F, Hoshi M, Perotti ME. Glycobiology 16 786-800 (2006)
  18. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). Sakuraba H, Matsuzawa F, Aikawa SI, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T. J Hum Genet 49 1-8 (2004)
  19. Human neutrophils secrete bioactive paucimannosidic proteins from azurophilic granules into pathogen-infected sputum. Thaysen-Andersen M, Venkatakrishnan V, Loke I, Laurini C, Diestel S, Parker BL, Packer NH. J. Biol. Chem. 290 8789-8802 (2015)
  20. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ. Balcewich MD, Stubbs KA, He Y, James TW, Davies GJ, Vocadlo DJ, Mark BL. Protein Sci. 18 1541-1551 (2009)
  21. Phylogenetic analyses suggest multiple changes of substrate specificity within the glycosyl hydrolase 20 family. Intra J, Pavesi G, Horner DS. BMC Evol. Biol. 8 214 (2008)
  22. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta. Akeboshi H, Chiba Y, Kasahara Y, Takashiba M, Takaoka Y, Ohsawa M, Tajima Y, Kawashima I, Tsuji D, Itoh K, Sakuraba H, Jigami Y. Appl. Environ. Microbiol. 73 4805-4812 (2007)
  23. Structure of N-acetyl-beta-D-glucosaminidase (GcnA) from the endocarditis pathogen Streptococcus gordonii and its complex with the mechanism-based inhibitor NAG-thiazoline. Langley DB, Harty DW, Jacques NA, Hunter N, Guss JM, Collyer CA. J. Mol. Biol. 377 104-116 (2008)
  24. Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes. Gloster TM, Vocadlo DJ. Curr Signal Transduct Ther 5 74-91 (2010)
  25. Role of active-site residues of dispersin B, a biofilm-releasing beta-hexosaminidase from a periodontal pathogen, in substrate hydrolysis. Manuel SG, Ragunath C, Sait HB, Izano EA, Kaplan JB, Ramasubbu N. FEBS J. 274 5987-5999 (2007)
  26. Gene expression and activity of cartilage degrading glycosidases in human rheumatoid arthritis and osteoarthritis synovial fibroblasts. Pásztói M, Nagy G, Géher P, Lakatos T, Tóth K, Wellinger K, Pócza P, György B, Holub MC, Kittel A, Pálóczy K, Mazán M, Nyirkos P, Falus A, Buzas EI. Arthritis Res. Ther. 11 R68 (2009)
  27. A novel beta-N-acetyl-D-hexosaminidase from the insect Ostrinia furnacalis (Guenée). Yang Q, Liu T, Liu F, Qu M, Qian X. FEBS J. 275 5690-5702 (2008)
  28. Molecular properties of the putative autolysin Atl(WM) encoded by Staphylococcus warneri M: mutational and biochemical analyses of the amidase and glucosaminidase domains. Yokoi KJ, Sugahara K, Iguchi A, Nishitani G, Ikeda M, Shimada T, Inagaki N, Yamakawa A, Taketo A, Kodaira K. Gene 416 66-76 (2008)
  29. Gaining insight into the inhibition of glycoside hydrolase family 20 exo-β-N-acetylhexosaminidases using a structural approach. Sumida T, Stubbs KA, Ito M, Yokoyama S. Org. Biomol. Chem. 10 2607-2612 (2012)
  30. Molecular cloning and crystal structural analysis of a novel beta-N-acetylhexosaminidase from Paenibacillus sp. TS12 capable of degrading glycosphingolipids. Sumida T, Ishii R, Yanagisawa T, Yokoyama S, Ito M. J. Mol. Biol. 392 87-99 (2009)
  31. Active-pocket size differentiating insectile from bacterial chitinolytic β-N-acetyl-D-hexosaminidases. Liu T, Zhang H, Liu F, Chen L, Shen X, Yang Q. Biochem. J. 438 467-474 (2011)
  32. Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes. Sayce AC, Alonzi DS, Killingbeck SS, Tyrrell BE, Hill ML, Caputo AT, Iwaki R, Kinami K, Ide D, Kiappes JL, Beatty PR, Kato A, Harris E, Dwek RA, Miller JL, Zitzmann N. PLoS Negl Trop Dis 10 e0004524 (2016)
  33. Synthesis, evaluation, and mechanism of N,N,N-trimethyl-D-glucosamine-(1→4)-chitooligosaccharides as selective inhibitors of glycosyl hydrolase family 20 β-N-acetyl-D-hexosaminidases. Yang Y, Liu T, Yang Y, Wu Q, Yang Q, Yu B. Chembiochem 12 457-467 (2011)
  34. The enzyme-binding region of human GM2-activator protein. Wendeler M, Werth N, Maier T, Schwarzmann G, Kolter T, Schoeniger M, Hoffmann D, Lemm T, Saenger W, Sandhoff K. FEBS J. 273 982-991 (2006)
  35. A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates. Tropak MB, Bukovac SW, Rigat BA, Yonekawa S, Wakarchuk W, Mahuran DJ. Glycobiology 20 356-365 (2010)
  36. Crystal structure of β-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James MN. J. Med. Chem. 54 1421-1429 (2011)
  37. 4-Deoxy-substrates for beta-N-acetylhexosaminidases: how to make use of their loose specificity. Slámová K, Gazák R, Bojarová P, Kulik N, Ettrich R, Pelantová H, Sedmera P, Kren V. Glycobiology 20 1002-1009 (2010)
  38. Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: identification of six novel alleles. Zampieri S, Filocamo M, Buratti E, Stroppiano M, Vlahovicek K, Rosso N, Bignulin E, Regis S, Carnevale F, Bembi B, Dardis A. Neurogenetics 10 49-58 (2009)
  39. Enzymatic characterization and molecular modeling of an evolutionarily interesting fungal β-N-acetylhexosaminidase. Ryšlavá H, Kalendová A, Doubnerová V, Skočdopol P, Kumar V, Kukačka Z, Pompach P, Vaněk O, Slámová K, Bojarová P, Kulik N, Ettrich R, Křen V, Bezouška K. FEBS J. 278 2469-2484 (2011)
  40. Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ. Knight EM, Williams HN, Stevens AC, Kim SH, Kottwitz JC, Morant AD, Steele JW, Klein WL, Yanagisawa K, Boyd RE, Lockhart DJ, Sjoberg ER, Ehrlich ME, Wustman BA, Gandy S. Mol. Psychiatry 20 109-117 (2015)
  41. Crystal structures of a glycoside hydrolase family 20 lacto-N-biosidase from Bifidobacterium bifidum. Ito T, Katayama T, Hattie M, Sakurama H, Wada J, Suzuki R, Ashida H, Wakagi T, Yamamoto K, Stubbs KA, Fushinobu S. J. Biol. Chem. 288 11795-11806 (2013)
  42. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice. Itakura T, Kuroki A, Ishibashi Y, Tsuji D, Kawashita E, Higashine Y, Sakuraba H, Yamanaka S, Itoh K. Biol. Pharm. Bull. 29 1564-1569 (2006)
  43. Interspecific analysis of the glycosidases of the sperm plasma membrane in Drosophila. Intra J, Cenni F, Pavesi G, Pasini M, Perotti ME. Mol. Reprod. Dev. 76 85-100 (2009)
  44. An alpha-subunit loop structure is required for GM2 activator protein binding by beta-hexosaminidase A. Zarghooni M, Bukovac S, Tropak M, Callahan J, Mahuran D. Biochem. Biophys. Res. Commun. 324 1048-1052 (2004)
  45. Sequencing, cloning and high-yield expression of a fungal β-N-acetylhexosaminidase in Pichia pastoris. Slámová K, Bojarová P, Gerstorferová D, Fliedrová B, Hofmeisterová J, Fiala M, Pompach P, Křen V. Protein Expr. Purif. 82 212-217 (2012)
  46. Structural basis of the GM2 gangliosidosis B variant. Matsuzawa F, Aikawa S, Sakuraba H, Lan HT, Tanaka A, Ohno K, Sugimoto Y, Ninomiya H, Doi H. J Hum Genet 48 582-589 (2003)
  47. Comparative Transcriptomic Exploration Reveals Unique Molecular Adaptations of Neuropathogenic Trichobilharzia to Invade and Parasitize Its Avian Definitive Host. Leontovyč R, Young ND, Korhonen PK, Hall RS, Tan P, Mikeš L, Kašný M, Horák P, Gasser RB. PLoS Negl Trop Dis 10 e0004406 (2016)
  48. Metabolism of vertebrate amino sugars with N-glycolyl groups: intracellular β-O-linked N-glycolylglucosamine (GlcNGc), UDP-GlcNGc, and the biochemical and structural rationale for the substrate tolerance of β-O-linked β-N-acetylglucosaminidase. Macauley MS, Chan J, Zandberg WF, He Y, Whitworth GE, Stubbs KA, Yuzwa SA, Bennet AJ, Varki A, Davies GJ, Vocadlo DJ. J. Biol. Chem. 287 28882-28897 (2012)
  49. Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation. Dersh D, Iwamoto Y, Argon Y. Mol. Biol. Cell 27 3813-3827 (2016)
  50. Characterization of seven novel mutations on the HEXB gene in French Sandhoff patients. Gaignard P, Fagart J, Niemir N, Puech JP, Azouguene E, Dussau J, Caillaud C. Gene 512 521-526 (2013)
  51. Characterization of the mutant β-subunit of β-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype. Yamada K, Takado Y, Kato YS, Yamada Y, Ishiguro H, Wakamatsu N. J. Biochem. 153 111-119 (2013)
  52. Chronic GM2 gangliosidosis type Sandhoff associated with a novel missense HEXB gene mutation causing a double pathogenic effect. Santoro M, Modoni A, Sabatelli M, Madia F, Piemonte F, Tozzi G, Ricci E, Tonali PA, Silvestri G. Mol. Genet. Metab. 91 111-114 (2007)
  53. Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo. Tropak MB, Yonekawa S, Karumuthil-Melethil S, Thompson P, Wakarchuk W, Gray SJ, Walia JS, Mark BL, Mahuran D. Mol Ther Methods Clin Dev 3 15057 (2016)
  54. Molecular and biochemical characterization of a novel β-N-acetyl-D-hexosaminidase with broad substrate-spectrum from the Aisan corn borer, Ostrinia furnacalis. Liu F, Liu T, Qu M, Yang Q. Int. J. Biol. Sci. 8 1085-1096 (2012)
  55. A crystal structure-guided rational design switching non-carbohydrate inhibitors' specificity between two β-GlcNAcase homologs. Liu T, Guo P, Zhou Y, Wang J, Chen L, Yang H, Qian X, Yang Q. Sci Rep 4 6188 (2014)
  56. Alterations in kidney tissue following zinc supplementation to STZ-induced diabetic rats. Karatug A, Kaptan E, Bolkent S, Mutlu O, Yanardag R. J Trace Elem Med Biol 27 52-57 (2013)
  57. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside. Sinici I, Yonekawa S, Tkachyova I, Gray SJ, Samulski RJ, Wakarchuk W, Mark BL, Mahuran DJ. PLoS ONE 8 e57908 (2013)
  58. Molecular properties of the glucosaminidase AcmA from Lactococcus lactis MG1363: mutational and biochemical analyses. Inagaki N, Iguchi A, Yokoyama T, Yokoi KJ, Ono Y, Yamakawa A, Taketo A, Kodaira K. Gene 447 61-71 (2009)
  59. Structural consequences of amino acid substitutions causing Tay-Sachs disease. Ohno K, Saito S, Sugawara K, Sakuraba H. Mol. Genet. Metab. 94 462-468 (2008)
  60. Characterization of the biosynthesis, processing and kinetic mechanism of action of the enzyme deficient in mucopolysaccharidosis IIIC. Fan X, Tkachyova I, Sinha A, Rigat B, Mahuran D. PLoS ONE 6 e24951 (2011)
  61. MS/MS fragmentation-guided search of TMG-chitooligomycins and their structure-activity relationship in specific β-N-acetylglucosaminidase inhibition. Usuki H, Yamamoto Y, Kumagai Y, Nitoda T, Kanzaki H, Hatanaka T. Org. Biomol. Chem. 9 2943-2951 (2011)
  62. Probing the Catalytic Mechanism of Vibrio harveyi GH20 β-N-Acetylglucosaminidase by Chemical Rescue. Meekrathok P, Suginta W. PLoS ONE 11 e0149228 (2016)
  63. Structural essentials for β-N-acetylhexosaminidase inhibition by amides of prolines, pipecolic and azetidine carboxylic acids. Glawar AF, Martínez RF, Ayers BJ, Hollas MA, Ngo N, Nakagawa S, Kato A, Butters TD, Fleet GW, Jenkinson SF. Org. Biomol. Chem. 14 10371-10385 (2016)
  64. Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil. Rozenberg R, Kok F, Burin MG, Sá Miranda MC, Vasques C, Henriques-Souza AM, Giugliani R, Vainzof M, Pereira LV. J. Child Neurol. 21 540-544 (2006)
  65. GlcNAc-Thiazoline conformations. Knapp S, Fash D, Abdo M, Emge TJ, Rablen PR. Bioorg. Med. Chem. 17 1831-1836 (2009)
  66. Isolation, purification, and biochemical characterization of two forms of lysosomal β-N-acetylhexosaminidase from the invertebrate Unio. Venugopal A, Sivakumar N. Biosci. Biotechnol. Biochem. 77 497-504 (2013)
  67. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease. Karumuthil-Melethil S, Nagabhushan Kalburgi S, Thompson P, Tropak M, Kaytor MD, Keimel JG, Mark BL, Mahuran D, Walia JS, Gray SJ. Hum. Gene Ther. 27 509-521 (2016)
  68. Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model. Kitakaze K, Mizutani Y, Sugiyama E, Tasaki C, Tsuji D, Maita N, Hirokawa T, Asanuma D, Kamiya M, Sato K, Setou M, Urano Y, Togawa T, Otaka A, Sakuraba H, Itoh K. J. Clin. Invest. 126 1691-1703 (2016)
  69. Letter A modeling study for structure features of β-N-acetyl-D-hexosaminidase from Ostrinia furnacalis and its novel inhibitor allosamidin: species selectivity and multi-target characteristics. Wang Y, Liu T, Yang Q, Li Z, Qian X. Chem Biol Drug Des 79 572-582 (2012)
  70. An integrated in silico approach to analyze the involvement of single amino acid polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 complex. Doss CG, Nagasundaram N. Cell Biochem. Biophys. 70 939-956 (2014)
  71. Assessing the severity of the small inframe deletion mutation in the alpha-subunit of beta-hexosaminidase A found in the Turkish population by reproducing it in the more stable beta-subunit. Sinici I, Tropak MB, Mahuran DJ, Ozkara HA. J. Inherit. Metab. Dis. 27 747-756 (2004)
  72. Exploring NAG-thiazoline and its derivatives as inhibitors of chitinolytic β-acetylglucosaminidases. Liu T, Xia M, Zhang H, Zhou H, Wang J, Shen X, Yang Q. FEBS Lett. 589 110-116 (2015)
  73. Genetics and Therapies for GM2 Gangliosidosis. Cachon-Gonzalez MB, Zaccariotto E, Cox TM. Curr Gene Ther 18 68-89 (2018)
  74. Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product. Li X, An Y, Liao J, Xiao L, Swanson M, Martinez-Fonts K, Pavon JA, Sherer EC, Jawa V, Wang F, Gao X, Letarte S, Richardson DD. Biotechnol Prog 37 e3128 (2021)
  75. Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis. Fitterer B, Hall P, Antonishyn N, Desikan R, Gelb M, Lehotay D. Mol. Genet. Metab. 111 382-389 (2014)
  76. Case Reports Infantile Sandhoff Disease: Unusual presentation. Muralidharan CG, Tomar RP. Med J Armed Forces India 72 S91-S93 (2016)
  77. Mechanism of Human Nucleocytoplasmic Hexosaminidase D. Alteen MG, Oehler V, Nemčovičová I, Wilson IB, Vocadlo DJ, Gloster TM. Biochemistry 55 2735-2747 (2016)
  78. Structural-Functional Analysis Reveals a Specific Domain Organization in Family GH20 Hexosaminidases. Val-Cid C, Biarnés X, Faijes M, Planas A. PLoS ONE 10 e0128075 (2015)
  79. A novel HEXB mutation and its structural effects in juvenile Sandhoff disease. Wang SZ, Cachón-González MB, Stein PE, Lachmann RH, Corry PC, Wraith JE, Cox TM. Mol. Genet. Metab. 95 236-238 (2008)
  80. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Vyas M, Deschenes NM, Osmon KJL, Chen Z, Ahmad I, Kot S, Thompson P, Richmond C, Gray SJ, Walia JS. Int J Mol Sci 24 14611 (2023)
  81. Functionality of a bicistronic construction containing HEXA and HEXB genes encoding β-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses. Shaimardanova AA, Chulpanova DS, Solovyeva VV, Aimaletdinov AM, Rizvanov AA. Neural Regen Res 17 122-129 (2022)
  82. Modification of the Thioglycosyl-Naphthalimides as Potent and Selective Human O-GlcNAcase Inhibitors. Shen S, Dong L, Chen W, Zeng X, Lu H, Yang Q, Zhang J. ACS Med Chem Lett 9 1241-1246 (2018)
  83. Structural basis of chitin utilization by a GH20 β-N-acetylglucosaminidase from Vibrio campbellii strain ATCC BAA-1116. Meekrathok P, Bürger M, Porfetye AT, Kumsaoad S, Aunkham A, Vetter IR, Suginta W. Acta Crystallogr D Struct Biol 77 674-689 (2021)
  84. Analysis of transition state mimicry by tight binding aminothiazoline inhibitors provides insight into catalysis by human O-GlcNAcase. Cekic N, Heinonen JE, Stubbs KA, Roth C, He Y, Bennet AJ, McEachern EJ, Davies GJ, Vocadlo DJ. Chem Sci 7 3742-3750 (2016)
  85. Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis. Deschenes NM, Cheng C, Ryckman AE, Quinville BM, Khanal P, Mitchell M, Chen Z, Sangrar W, Gray SJ, Walia JS. Int J Mol Sci 24 9217 (2023)
  86. Canine GM2-Gangliosidosis Sandhoff Disease Associated with a 3-Base Pair Deletion in the HEXB Gene. Wang P, Henthorn PS, Galban E, Lin G, Takedai T, Casal M. J. Vet. Intern. Med. 32 340-347 (2018)
  87. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts. Kitakaze K, Tasaki C, Tajima Y, Hirokawa T, Tsuji D, Sakuraba H, Itoh K. Biochem Biophys Rep 7 157-163 (2016)
  88. Computational Studies on the Potency and Selectivity of PUGNAc Derivatives Against GH3, GH20, and GH84 β-N-acetyl-D-hexosaminidases. Dong L, Shen S, Xu Y, Wang L, Feng R, Zhang J, Lu H. Front Chem 7 235 (2019)
  89. Computational Study for the Unbinding Routes of β-N-Acetyl-d-Hexosaminidase Inhibitor: Insight from Steered Molecular Dynamics Simulations. Hu S, Zhao X, Zhang L. Int J Mol Sci 20 (2019)
  90. Crystal structure of native β-N-acetylhexosaminidase isolated from Aspergillus oryzae sheds light onto its substrate specificity, high stability, and regulation by propeptide. Škerlová J, Bláha J, Pachl P, Hofbauerová K, Kukačka Z, Man P, Pompach P, Novák P, Otwinowski Z, Brynda J, Vaněk O, Řezáčová P. FEBS J. 285 580-598 (2018)
  91. Expression of human β-N-acetylhexosaminidase B in yeast eases the search for selective inhibitors. Krejzová J, Kulik N, Slámová K, Křen V. Enzyme Microb. Technol. 89 1-6 (2016)
  92. Case Reports Identification of a novel HEXB Mutation in an Iranian Family with suspected patient to GM2-gangliosidoses. Mansouri-Movahed F, Akhoundi F, Nikpour P, Garshasbi M, Emadi-Baygi M. Clin Case Rep 8 2583-2591 (2020)
  93. Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses. Benzie G, Bouma K, Battellino T, Cooper S, Hemming R, Kammouni W, Liu L, Do C, Khajehpour M, Perreault H, Kornfeld S, Triggs-Raine B, Mark BL. BBA Adv 2 100032 (2022)
  94. Integrated Computational Analysis Highlights unique miRNA Signatures in the Subventricular Zone and Striatum of GM2 Gangliosidosis Animal Models. Morena F, Oikonomou V, Argentati C, Bazzucchi M, Emiliani C, Gritti A, Martino S. Int J Mol Sci 20 (2019)
  95. Letter Letter to the Editor. Mark BL, Mahuran D. Mol Ther 29 3 (2021)
  96. Michael James (1940-2023). Glover JNM, Kay CM, Lemieux J, Read RJ. Acta Crystallogr D Struct Biol 79 953-955 (2023)
  97. Molecular pathology of Sandhoff disease with p.Arg505Gln in HEXB: application of simulation analysis. Yasui N, Takaoka Y, Nishio H, Nurputra DK, Sekiguchi K, Hamaguchi H, Kowa H, Maeda E, Sugano A, Miura K, Sakaeda T, Kanda F, Toda T. J. Hum. Genet. 58 611-617 (2013)
  98. Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses. Cavender C, Mangini L, Van Vleet JL, Corado C, McCullagh E, Gray-Edwards HL, Martin DR, Crawford BE, Lawrence R. PLoS One 15 e0243006 (2020)
  99. Novel HEXA variants in Korean children with Tay-Sachs disease with regression of neurodevelopment from infancy. Park JH, Ko JM, Kim MS, Kim MJ, Seong MW, Yoo T, Lim BC, Chae JH. Mol Genet Genomic Med 9 e1677 (2021)
  100. Nucleotide binding as an allosteric regulatory mechanism for Akkermansia muciniphila β-N-acetylhexosaminidase Am2136. Li CC, Yi H, Wang YM, Tang XY, Zhu YB, Song YJ, Zhao NL, Huang Q, Mou XY, Luo GH, Liu TG, Yang GL, Zeng YJ, Wang LJ, Tang H, Fan G, Bao R. Gut Microbes 14 2143221 (2022)